Manufactured Object
Merck & Co. breaks ground on $1B future US home of Keytruda
United States, Keytruda, Home environment, Merck, Wilmington, Biological Factors
AstraZeneca’s China woes recede as focus shifts to upcoming readouts
$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition
Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies
Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns
Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M
Biohaven, Oberland Capital, $600 million investment, troriluzole, spinocerebellar ataxia (SCA), non-dilutive funding, FDA approval, senior secured notes
Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects
Reindeer, CAR-T, Staff, Neoplasms, Cell Therapy, Allogeneic CRISPR-edited Anti-CD19 CAR-T Cells CB-010, Clustered Regularly Interspaced Short Palindromic Repeats, Leukemia, Myelocytic, Acute, United States Food and Drug Administration, 32%
Compounding pharmacies dealt a blow in fight over end of semaglutide shortage
United States Food and Drug Administration, semaglutide, Compound, enforcement, Pharmacy facility, shortage, Wegovy
Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending
United States, Investments, Manufacture, Martes pennanti, Science, development aspects, Thermo Fisher
Mercks Gardasil sales sink further amid China market pressure
Market, China, Gardasil, Gardasil sales, Pressure- physical agent, Growth, China
Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations
EU, Novartis, CEOs, Transplant Registry Unified Management Program, Financial cost, Parity, sanofi, Investments, Prices, Pharma, Market, nations, U.S.
Lotte Bio launches ADC services; Ypsomed to focus on self-injection business
Antibody-Drug Conjugates, Lotte, Ypsomed, Services, Biological Factors, Manufacture, self-injection business